ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR191/059/SRR19174559/SRR19174559.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR191/057/SRR19174557/SRR19174557.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR191/062/SRR19174562/SRR19174562.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR191/058/SRR19174558/SRR19174558.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR191/061/SRR19174561/SRR19174561.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR191/060/SRR19174560/SRR19174560.fastq.gzprimaryOK200GenomicsMaria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branchhttps://www.ebi.ac.uk/ena/browser/view/PRJNA837373Actinomycin D and nutlin-3a act synergistically in activation of p53 transcription factor and, consequently, synergistically activate a subset of p53-regulated genes. The goal was to compare transcriptome changes of cell lines derived from three different cancers. The cells grew in control conditions or were exposed for 30 hours to 5nM actinomycin D and 5 uM nutlin-3a.xref:EuropePMC:PMC11274236ENAActinomycin, U2OS, human being, A375 cell, Transcriptome Profile, ActD, Neoplasms, Benign Neoplasm, Gene Expression Profile, Gene, 13)oxatetra-azacyclohexadecin-10-yl)-4, Profiles, Tumor, Malignant, 10, Human, 11, Homo sapiens, Cosmegen., Line, 4, 5, Cosmegen Lyovac, 7, Man, treatment, NCI-460, 1-i)(1, 13-bis(1-methylethyl)-1, Man (Taxonomy), Malignancy, Profile, 9-dicarboxamide, man, Signatures, Actinomycin D, Neoplasias, Expression Signature, malignant neoplasm, A-375, A375, Lyovac Cosmegen, disease management, Transcriptomes, Therapies, Malignancies, 9-trimethyl-6, Cancer, Tumors, Therapy, Transcriptome, H460, Malignant Neoplasm, Modern, Expression Profiles, Cell Lines, NCI-H460, LyovacCosmegen, U-2 OS, Cell, Cosmegen, actinomycin IV, whole transcriptome, Gene Expression, MT, Benign, Expression Signatures, Gene Expression Signatures, Neoplasm, Gene Expression Signature, N'-bis(hexadecahydro-2, 14-pentaoxo-1H-pyrrolo(2, Expression Profile, actinomycin C1, Transcriptome Profiles, Lines, primary cancer, Lyovac-Cosmegen, 2-amino-N, Benign Neoplasms, 6-dimethyl-3-oxo-3H-phenoxazine-1, Cancers, Treatments, malignant tumor, human, Malignant Neoplasms, H-460, Therapeutic, Gene Expression Profiles, Dactinomycin, Modern Man, NCI-HUT-460, Treatment, Meractinomycin, Signature, Lyovac, NeoplasiafalseTranscriptome changes following treatment of three human cancer cell lines (U-2 OS, NCI-H460, A375) with actinomycin D and nutlin-3a.2023-05-192022-05-13PRJNA837373